

AMICUS THERAPEUTICS INC  
Form 8-K  
January 09, 2012

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 9, 2012**

**AMICUS THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

**001-33497**

**71-0869350**

(State or other jurisdiction  
of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

**6 Cedar Brook Drive,  
Cranbury, NJ**

**08512**

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: **(609) 662-2000**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events.**

On January 12, 2012, John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc. (the Company), will participate in the 30<sup>th</sup> Annual J.P. Morgan Healthcare Conference (the Conference). A copy of the presentation to be given by Mr. Crowley at the Conference is attached to this Current Report as Exhibit 99.1. In addition, on January 9, 2012, the Company filed a press release, a copy of which is attached to this Current Report as Exhibit 99.2.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits: The Exhibit Index annexed hereto is incorporated herein by reference.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Amicus Therapeutics, Inc.

Date: January 9, 2012

By: /s/ Geoffrey P. Gilmore  
Geoffrey P. Gilmore  
Senior Vice President and General  
Counsel

---

**EXHIBIT INDEX**

Exhibit No.	Description
99.1	Presentation Materials
99.2	Press Release dated January 9, 2012